BRIEF-CTi Biopharma announces phase 3 data from the PERSIST-2 trial of Pacritinib to be presented in late-breaking session at ASH annual meeting

* CTi Biopharma announces phase 3 data from the PERSIST-2

trial of Pacritinib to be presented in late-breaking session at

ASH annual meeting

Source text for Eikon:

Further company coverage:

Read more